ArticleTranslational cancer research2025
Survival analysis of gastric malignancy patients: identifying key prognostic factors.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Survival outcomes in early gastric cancer: evidence from SEER-based population studies.Journal of gastrointestinal oncology · 2026Article
- Prognostic factors for overall survival in patients with early gastric cancer: a retrospective cohort study based on SEER database.Journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric malignancies are common worldwide, with a high incidence rate and mortality. Relevant studies are needed to further demonstrate the harmfulness of gastric malignancies to promote awareness of its prevention. The aim of the study was to analyze the clinicopathological features and prognosis of gastric malignancies. Methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to obtain the clinical data of 122,793 patients diagnosed with gastric malignancies from 2000 to 2019. Along with performing univariate and multivariate analyses, the associated survival rates of each variable were analyzed using SPSS software. Columnar line graph prediction models were developed and validated using R software. Results: In total, 122,793 gastric malignancy patients were included in this study, including 74,303 males (60.5%) and 48,490 females (39.5%). The predominant age group among patients was 60-74 years, comprising a total of 45,603 individuals (37.1%). The follow-up time was 0-239 months, the median follow-up time was 11.7 months, and 91,869 patients (74.8%) died. Gastric adenocarcinoma was the main pathological type, accounting for 96,259 patients (82.7%). The main disease site was the cardia of the stomach, accounting for 34,019 patients (34.0%); most (109,706; 89.3%) patients lived in cities. Univariate and multivariate analyses showed that gender, age, tumor size, tumor location, American Joint Committee on Cancer (AJCC) stage, pathological type, rural/urban, and treatment were independent risk factors for prognosis (P<0.001). The Concordance index (C-index) of the nomogram prognostic model was 0.763±0.002, and the areas under the receiver operating characteristic (ROC) curve (AUC) of the 1-, 3-, and 5-year survival rates were 0.76, 0.79, and 0.79, respectively. The calibration curve showed that the predicted survival rate of the nomogram was in good agreement with the observed survival rate. Conclusions: The prognosis for tumors located in the greater curvature of the stomach is relatively favorable. The level of care available in a patient's city is directly correlated with their prognosis. Notably, the outcomes for gastric stromal tumors (GSTs) and gastric neuroendocrine neoplasms (G-NENs) are significantly more favorable compared to other pathological types. Patients who meet surgical criteria should undergo surgery as early as possible to enhance survival duration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.